Back to Search
Start Over
Dual Targeted Therapy: a possible option for the management of refractory Inflammatory Bowel Disease
- Publication Year :
- 2020
-
Abstract
- Background and Aims Dual targeted therapy [DTT] has been proposed as a novel therapeutic strategy for the management of complicated patients with inflammatory bowel diseases [IBD]. Our aim here was to investigate the safety and effectiveness of this approach in a real-life setting. Methods We retrospectively extracted data from IBD patients receiving DTT in Italian IBD referral centres. Baseline characteristics, clinical activity of intestinal and extra-intestinal disease, and C-reactive protein levels were recorded. All adverse events were reported. Clinical effectiveness, biochemical remission and safety of DTT were investigated. Results Sixteen patients were identified; indications for DTT were: ‘active IBD’ or ‘active EIM’ despite ongoing biological therapy. The most commonly used DTT were: vedolizumab + ustekinumab [three patients] and vedolizumab + adalimumab [three patients]. Clinical response of intestinal or extra-intestinal symptoms, according to the indication for DTT, was reported by all patients by the end of the induction. Four patients discontinued DTT during follow-up. Three patients experienced an adverse event; no serious adverse event was reported. Conclusions DTT seems to be an effective and safe treatment and may represent an appealing therapeutic strategy for the management of complicated IBD patients.
- Subjects :
- medicine.medical_specialty
Combination therapy
medicine.medical_treatment
Settore MED/12 - GASTROENTEROLOGIA
Disease
Biologics
Inflammatory bowel disease
Targeted therapy
Vedolizumab
03 medical and health sciences
0302 clinical medicine
Internal medicine
Ustekinumab
Adalimumab
medicine
Adverse effect
Extraintestinal manifestations
Combination Therapy
business.industry
Gastroenterology
food and beverages
General Medicine
medicine.disease
carbohydrates (lipids)
030220 oncology & carcinogenesis
030211 gastroenterology & hepatology
business
medicine.drug
Subjects
Details
- Language :
- English
- Database :
- OpenAIRE
- Accession number :
- edsair.doi.dedup.....51cef34d504ef6474041c92cbc8da671